Markets, wholesales, and distributes healthcare products. Markets, wholesales, and distributes medical products. Now — the numbers.
This is an established company with proven profits.
Average growth of 5% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.2B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 8.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
It pays out $1.44 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
Against everything we grade, EBOSY lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EBOSY does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.